Document:

CONFIDENTIAL TREATMENT REQUESTED	EXHIBIT 10.19 

CONFIDENTIAL TREATMENT REQUESTED
UNDER RULE 24(b)(2) OF THE SECURITIES AND EXCHANGE ACT OF 1934. CONFIDENTIAL TREATMENT
IS REQUESTED AND IS NOTED WITH “[CONFIDENTIAL TREATMENT REQUESTED].”
AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN PREVIOUSLY FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

COLLABORATIVE RESEARCH

AGREEMENT
BETWEEN
UNIVERSITY OF BRADFORD
AND SOMANTA INCORPORATED  

CONFIDENTIAL TREATMENT
REQUESTED 

Collaborative Research
Agreement 

This agreement dated the 1st day of
March 2006 is between: 

     	(1)	
          UNIVERSITY OF BRADFORD (” The University”) established in
          England whose principal address is Richmond Road, Bradford, BD7 1DP, UK; and 

          

     	(2)	
          SOMANTA Incorporated (“Somanta”) a company incorporated in the
          United States under the law of Delaware with a registered office at 80 Harley
          Street, London, W1G 7HL, UK. 

          

RECITALS: 

     	A.	
          Somanta and The University intend to enter into a research collaboration
          agreement under which The University shall conduct further research funded by
          Somanta on the invention(s) disclosed by The Patents, which are owned by or
          exclusively licensed to Somanta. 

          

IT IS AGREED as follows: 

1. Definitions 

In this Agreement the following words
shall have the following meanings: 

			
	1.1	"Background Information"	any information and/or Know-how made available by
			either party to the other party pursuant to Clause 4.1;
	
1.2	
"Commencement Date"	
The Commencement Date shall be the date of signing
			this Agreement;
	
1.3	
"Intellectual Property"	
means all of the following and as they exist in all
			jurisdictions throughout the world:
	
	
	
1.3.1    patents, patent applications and inventions,
			 designs and improvements described and claimed
			therein, patentable inventions and other patent rights
			(including any divisions, continuations,continuations-
			in-part, substitutions, or reissues thereof, whether or not 
			patents are issued on any such applications and whether 
			or not any such applications are modified, withdrawn, or;
			resubmitted);
	
	
	
1.3.2    trademarks, service marks, trade dress, trade
			names, brand names, designs, logos, or corporate names,
			whether registered or unregistered, and all registrations
			and applications for registration thereof; and

CONFIDENTIAL TREATMENT
REQUESTED 

			
			
	
	
	1.3.3     copyrights, including all renewals and extensions
			thereof, copyright registrations and applications for
			 registration thereof.
	
1.4	
"Background Intellectual	
Intellectual Property previously developed and owned or
		Property"	exclusively licensed to the respective parties which is
			required for carrying out the responsibilities in the
			Research Project pursuant to Clauses 4.2 and 4.3 and
			Schedule 2;
	
1.5	
"Know-how"	
All technical information in the Field created during
			research carried out by The University under the
			direction of Prof. Laurence Patterson in the possession
			of The University relating directly to the inventions
			claimed in The Patents;
	
1.6	
"The Patents"	
[CONFIDENTIAL TREATMENT REQUESTED]
	
1.7	"Patent A"	[CONFIDENTIAL TREATMENT REQUESTED]
	
1.8	"Patent B"	[CONFIDENTIAL TREATMENT REQUESTED]
	
1.9	
"Payment Schedule"	
The payments due to be paid by Somanta to The
			University for research conducted under the agreed
			 Project Plan and set out in Schedule 1 and Clause 3.1.
	
1.10	
"Project Intellectual	
All Intellectual Property arising out of the Research
		 Property"	Project within the Project Plan including, without
			limitation, the Project Information;
	
1.11	
"Project Information"	
all discoveries, inventions, whether patentable or not,
			results, data, analyses, designs, formulae, processes,
			specifications, reports, methods, Know-how, trade
			secrets, drawings or other information arising out of the
			Research Project;
	
1.12	
"Project Plan"	
the timetable, research and development objectives, 
			deliverables and plan of work for the Research Project 
			agreed by The University and Somanta, and set out in 
			Schedule 2 as may be amended from time to time;
	
1.13	
"University's Project	
the work to be carried out by The University under the 
		Responsibilities"	Research Project as described in Schedule 2 as may be 
			amended from time to time;

CONFIDENTIAL TREATMENT
REQUESTED 

			
			
	1.14	"University's Project	including Prof. Laurence Patterson and his research 
		Scientists"	team (employed by The University) and any 
			replacements thereof;
	
1.15	
"University's Project Team"	
The University's Project Scientists and any other 
			individuals involved in the Research Project by The
			University;
	
1.16	
"Field"	
Area of scientific research undertaken by the University 
			Project Team to complete the Research Project;
	
1.17	
"The Research Project"	
The research undertaken as described in the Project Plan
			and performed by The University's Project Team;
	
1.18	"The Research Team"	The team involved in the delivery of the research 
			collaboration including the University's Project Team 
			and those individuals involved in the research either 
			directly or indirectly at Somanta;

CONFIDENTIAL TREATMENT
REQUESTED 

	2.  	The
Research Project

	2.1 	The
University shall carry out its Project Responsibilities with reasonable skill and care,
and in accordance with the timetable and scope set out specifically in the Project Plan
(Schedule 2) in connection to The Patents which is the condition precedent of the
Research Project. 

	2.2 	At
the end of each three month period, The University shall notify Somanta with a progress
report on the Research Project setting out the following:- 

	2.2.1  	the
work which The University has carried out on the Research Project during the previous
three months; 

	2.2.2  	any
data and/or results obtained during the previous three months;

	2.2.3  	the
work that The University intends to carry out during the next three months; and

	2.2.4 	details
of any inventions made in the course of carrying out the Research Project as described in
the Project Plan. 

	2.3 	Within
14 days of the end of each calendar quarter the parties shall meet to discuss progress on
the Research Project in general and in particular The University’s latest progress
report submitted under Clause 2.2. The University shall procure that the Project
Scientists shall attend such meetings together with such other members of the University’s
Project Team as Somanta may reasonably request. This meeting should occur at a
destination and time previously agreed by both parties and at Somanta’s expense. 

	2.4 	The
University shall use The University’s Project Scientists to carry out and/or
supervise The University’s Project Responsibilities. If, due to circumstances beyond
the reasonable control of The University, it is necessary to replace any of the University’s
Project Scientists then the parties shall promptly meet to discuss potential replacements
of equivalent qualification and experience in the Field. The University shall not replace
any of The University’s Project Scientists on the Research Project without the prior
written approval of Somanta. 

CONFIDENTIAL TREATMENT
REQUESTED 

	2.5 	The
University shall have discretion following consultation with Somanta to replace other
members of The University’s Project Team during the Research Project with
replacements of appropriate qualifications, skills and experience in the Field. 

	3.  	Payment 

	3.1 	In
consideration of The University complying with its obligations under this Agreement,
Somanta shall pay to The University the amounts set out in the Payment Schedule paid
quarterly, in arrears from the Commencement Date. 

	3.2  	All
sums due under this Agreement shall be paid in [CONFIDENTIAL TREATMENT REQUESTED].

	3.3 	Sums
specified in this Agreement in relation to the Payment Schedule are [CONFIDENTIAL
TREATMENT REQUESTED] of Value Added Tax. 

CONFIDENTIAL TREATMENT
REQUESTED 

	4.  	Ownership
and Use of Background Information, Background Intellectual Property and the Project
Intellectual Property

	4.1 	Each
party shall make available to the other such of its Background Information as may assist
the other party in carrying out its responsibilities under the Research Project provided
that nothing in this Clause 4.1 shall oblige either party to act in breach of a
confidentiality obligation owed to any third party. 

	4.2 	Ownership
of Background Intellectual Property shall remain vested in the party making such
Background Intellectual Property available. 

	4.3 	Each
party hereby grants to the other a non-exclusive, non-transferable, non-sublicensable,
royalty-free licence to make use of its Background Intellectual Property solely for
the purposes of carrying out its responsibilities under the Research Project. 

	4.4 	Somanta
shall own the entire right, title and interest in and to all Project Intellectual
Property discovered, developed, or invented in the course of performing the Research
Project as defined within the Project Plan or otherwise related to Alchemix or Prodrax,
whether solely by a party or jointly by the parties subject to clause 4.5. The University
hereby assigns to Somanta all right, title and interest, if any, The University has in
any Project Intellectual Property; provided that in the event that the foregoing
assignment would be void or impermissible, then The University automatically shall be
deemed to have granted to Somanta the perpetual, irrevocable, fully paid-up, freely
sub-licensable license to use and practice such Project Intellectual Property for any and
all purposes, which license shall be exclusive to Somanta, and which license shall
survive any expiration or termination of this Agreement. Notwithstanding the foregoing,
Somanta hereby grants to The University a perpetual, irrevocable, royalty-free,
non-sublicensable license to use and practice Project Intellectual Property solely for
non-commercial research purposes. University hereby agrees that any and all University
employees, students or any other persons who provide services in connection with
the Research Project will have assigned any and all rights such employee, student
or any other person may obtain in any technology or other information by virtue of
such services to the University.

CONFIDENTIAL TREATMENT
REQUESTED 

	4.5 	Somanta
shall have the exclusive right to apply for patents in respect of improvements and/or
inventions made in the course of the Research Project within The Project Plan and The
University shall provide Somanta with such assistance as Somanta shall from time to time
request with the filing and prosecution of such patent applications, entirely at Somanta’s
expense. 

	4.6 	For
the avoidance of doubt, notwithstanding Clause 4.4, The University and Somanta shall own
the Intellectual Property, improvements and inventions created or arising outside The
Project Plan and unrelated to either Alchemix or Prodrax jointly or solely
in accordance of contribution of each party; provided, however, that University
hereby grants to Somanta an option (right of first refusal) to license such
Intellectual Property and improvements based on fair and reasonable commercial terms
following negotiation with The University. 

	5.  	Confidential
Information and Publications 

	5.1  	In
this Agreement, subject to Clause 5.2:- 

	 	5.1.1 	“Confidential
Information” belonging to Somanta shall mean Somanta’s Background Information,
the Project Information and any other information disclosed to The University by Somanta
relating to Somanta’s business, technical and/or research plans; 

		5.1.2 	
“Confidential Information” belonging to The University shall mean The
University’s Background Information. 

CONFIDENTIAL TREATMENT
REQUESTED 

	5.2  	"Confidential
Information" shall not include any information which:-

	5.2.1  	is
or  becomes  public  knowledge  through no  improper  conduct  on the part of the party
 receiving  the          Confidential Information; and/or

	5.2.2  	is
already  lawfully  possessed by the party  receiving  Confidential  Information  prior to
receiving it;          and/or

	5.2.3 	is
obtained subsequently from a third party without any obligations of confidentiality and
such third party is in lawful possession of such material and is not in violation of any
contractual or legal obligation to maintain the confidentiality of such material. 

	5.3 	The
onus shall be on the party asserting that any of the exceptions set out in Clause 5.2
apply to prove, by competent written evidence, that such exceptions apply. 

	5.4 	Each
party shall, and shall procure that its respective employees and members of the Research
Team shall keep confidential all Confidential Information belonging to the other party
and shall not use any Confidential Information belonging to the other party other than
for the purposes of carrying out the Research Project and/or exercising its rights
hereunder. 

	5.5  	Each
party shall take all reasonable steps to:-

	5.5.1 	ensure
that only the Research Team and other necessary personnel shall have access to
Confidential Information belonging to the other party; and 

	5.5.2 	ensure
that its Research Team members use Confidential Information belonging to the other party
for the sole purpose of carrying out the Research Project or exercising its rights
hereunder. 

CONFIDENTIAL TREATMENT
REQUESTED 

	5.6 	Each
party shall procure that each of its employees and members of the Research Team are bound
by appropriate confidentiality and non-use obligations in respect of Confidential
Information belonging to the other party. 

	5.7  	The
University  shall be entitled to publish the results of work carried out by The
 University  under the          Research Project provided that:-

	5.7.1 	All
proposed publications (including, but not limited to, scientific publications, patent
applications and non-confidential presentations), shall be submitted in writing to
Somanta for review at least thirty (30) days before submission for publication or before
presentation. Somanta may require the deletion from the publication of any Background
Intellectual Property or Information, or an amendment to the publication through which
commercially sensitive Background Intellectual Property and/or Information is disguised
to the satisfaction of Somanta. Somanta may also request the delay of the publication if
in it’s opinion the delay is necessary in order to seek patent or similar protection
to Project Intellectual Property. Any delay imposed on publication shall not last longer
than is reasonably necessary to obtain the required protection; and shall not exceed six
(6) months from the date of receipt of the proposed publication by Somanta. Notification
of the requirement for delay in publication must be received by the University within
thirty (30) days after receipt of the proposed publication by Somanta, failing which the
University shall be free to assume that Somanta has no objection to the proposed
publication and 

	5.7.2 	the
proposed publication does not contain any Confidential Information belonging to Somanta,
unless Somanta has consented thereto in writing. 

	5.8 	Any
publication of the results of the Research Project shall acknowledge the assistance of
Somanta and will include Somanta collaborators as co-authors whenever it applies. 

	5.9 	The
obligations of confidentiality and non-use set out in this Clause 5 shall remain in force
and shall be binding upon the parties for so long as any party has knowledge or
possession of any Confidential Information belonging to the other party and for the
avoidance of doubt shall survive any termination or cancellation of this Agreement. 

CONFIDENTIAL TREATMENT
REQUESTED 

	6.  	Duration
and Termination 

	6.1 	This
Agreement shall commence on the Commencement Date and shall expire on completion of the
Research Project unless sooner terminated in accordance with the provisions of this
Clause 6. 

	6.2  	Either
party may terminate this Agreement forthwith if:-

	6.2.1 	the
other party breaches any provision of this Agreement and, having been notified of such
breach, fails to remedy it within 30 days of notification; or 

	6.2.2  	any
of the following events occur:-

	6.2.2.1 	  an
order is made or a resolution passed for the winding up of the other party (other than
for the purpose of a solvent scheme of reconstruction or amalgamation); 

	6.2.2.2 	  an
administration, administrative receiver or receiver is appointed in respect of a material
part of the other party’s assets or business; or 

	6.2.2.3 	  as
a consequence of financial difficulties the other party makes any voluntary arrangement
with its creditors; or 

	6.2.2.4  	  the
other party ceases to continue its business; or

	6.2.2.5  	  the
other party becomes unable to pay its debts as and when they fall due;

	6.2.2.6 	  as
a consequence of debt and/or maladministration, the other party takes or suffers any
similar or analogous action to those listed in Clauses 6.2.2.1 to 6.2.2.3 above. 

	6.2.2.7  	  The
Patents or the licence of The Patents becomes invalid, expired or terminated. 

CONFIDENTIAL TREATMENT
REQUESTED 

	7.  	Consequences
of Expiry and Termination 

	7.1  	On
expiry or termination of this Agreement for any reason:-

	7.1.1 	Subject
to Clause 7.1.2, each party shall return all materials containing any Background
Information in its possession or control to the party which made such Background
Information available; 

	7.1.2 	The
University shall immediately hand over to Somanta all samples or other materials
containing any Project Information in its possession or control; and 

	7.1.3 	Subject
to Clause 7.2, the provisions of Clauses 4.2, 4.4 to 4.6 inclusive, 5and 7 shall
continue in full force and effect. 

	7.2 	Expiry
and termination of this Agreement shall be without prejudice to any other right or remedy
for breach of this Agreement which either party may have which accrued on or prior to the
date of expiry or termination. 

	8.  	General 

	8.1  	Notices 

	8.1.1 	Any
notice or other communication given under this Agreement shall be in writing and shall be
sent by pre-paid first class mail or by fax (confirmed by pre-paid first class mail
placed in the post on or on the day after the date of transmission) to the other party at
the address set out at the beginning of this Agreement or to such other address or fax
number as may from time to time be notified to the other party in writing. 

	8.1.2 	Any
notice so sent by pre-paid first class mail shall be deemed to have been given on the
third business day from and including the date of posting. Any notice so sent by fax (and
confirmed by first class mail as aforesaid) shall be deemed to have been given the next
business day following the day of transmission. 

CONFIDENTIAL TREATMENT
REQUESTED 

	8.2  	Severability 

	  	If any
provision of this Agreement is declared by any judicial or other competent authority to
be void, voidable, illegal or otherwise unenforceable then the remaining provisions of
this Agreement shall continue in full force and effect. The judicial or other competent
authority making such determination shall have the power to limit, construe or reduce the
duration, scope, activity and/or area of such provision, and/or delete specific words or
phrases as necessary to render, such provision enforceable. 

	8.3  	Waiver 

	  	Failure or
delay by any party to exercise any right or remedy under this Agreement shall not be
deemed to be a waiver of that right or remedy, or prevent it from exercising that or any
other right or remedy on that occasion or on any other occasion. 

	8.4  	Entire
Agreement and Amendments 

	8.4.1 	This
Agreement constitutes the entire agreement and understanding of the parties relating to
the subject matter of this Agreement and supersedes all prior oral or written agreements,
representations, understandings or arrangements between the parties. 

	8.4.2 	The
parties acknowledge that they are not relying on any agreement, understanding,
arrangement, warranty, representation or term which is not set out in this Agreement. 

	8.4.3  	Nothing
in this Clause 8.4 shall operate to:-

	8.4.3.1  	  exclude
any provision implied into this Agreement by law and which may not be excluded by law; or

CONFIDENTIAL TREATMENT
REQUESTED 

	8.4.3.2  	  limit
or exclude any liability, right or remedy to a greater extent than is permissible under
law. 

	8.4.4 	No
change may be made to this Agreement except in writing signed by the duly authorised
representatives of each of the parties. 

	8.4.5 	Either
party may propose changes to the Project Plan (described in Schedule 2). Proposed changes
must be agreed to in writing by both parties. Appropriate changes to the budget
(Schedule 1) will be agreed to in writing prior to implementation of any Project
Plan changes.

	8.5  	Relationship
of the Parties 

	8.5.1 	Nothing
in this Agreement shall create evidence or imply any agency, partnership or joint venture
between the parties. 

	8.5.2 	No
party shall act or describe itself as the agent of any of the other parties nor shall a
party represent that it has any authority to make commitments on behalf of the other
parties. 

	8.6  	Assignment
and Sub-contracting 

	  	This Agreement
is personal to the parties and neither party shall assign, transfer, sub-license,
sub-contract, charge, or otherwise deal in its rights or obligations under this Agreement
except in the circumstance whereby Somanta undergoes a merger, consolidation or sale of
substantially all its assets in which case it may assign this Agreement to any party in
conjunction with the aforementioned. 

CONFIDENTIAL TREATMENT
REQUESTED 

	8.7  	Publicity 

	  	Except as
required by law or regulation and subject to clause 5.7, no one shall make any
announcement, or comment upon, or originate any publicity, or otherwise provide any
information to any third party (other than its legal advisors) concerning this Agreement
(including without limitation the existence of this Agreement, the performance of this
Agreement and/or any dispute, arbitration or disagreement relating to this Agreement)
without the prior written consent of the other parties. The parties acknowledge that
Somanta is required to include a description of this Agreement, with a copy attached, in
its regulatory filings. 

	8.8  	Further
Assurances 

	  	As and
when requested by another party, each party shall, and shall procure that their
respective employees shall, do all acts and execute all documents as may be reasonably
necessary to give effect to the provisions of this Agreement. 

	8.9  	Headings 

	  	The headings
used in this Agreement are for convenience only and shall not affect the interpretation
of this Agreement. 

	8.10  	University’s
Project Team 

	  	In this
Agreement, unless the context otherwise requires, an obligation by The University to do,
or not to do, an act shall be deemed to include an obligation on The University to
procure that each member of The University’s Project Team shall do, or not do, that
act. 

CONFIDENTIAL TREATMENT
REQUESTED 

	8.11  	Law
and Jurisdiction 

	  	The validity,
construction and performance of this Agreement shall be governed by English law and the
parties accept the exclusive jurisdiction of the English courts in respect thereof. 

SIGNED ON BEHALF OF THE
UNIVERSITY OF BRADFORD: 

SIGNATURE: /s/ R.J. Andrew 

NAME :R.J. Andrew 

POSITION : Registrar and
Secretary 

DATE: February 22, 2006 

SIGNED ON BEHALF OF
SOMANTA: 

SIGNATURE: /s/ Agamemnon
Epenetos 

NAME : Agamemnon Epenetos 

POSITION : CEO 

DATE: February 17, 2006 

CONFIDENTIAL TREATMENT
REQUESTED 

Schedule 1 

The Payment Schedule

[CONFIDENTIAL TREATMENT REQUESTED] 

CONFIDENTIAL TREATMENT
REQUESTED 

Schedule 2 

The Project Plan

[CONFIDENTIAL TREATMENT REQUESTED]EXHIBIT 4.1

================================================================================

                            THE ALLSTATE CORPORATION
                                       TO

                   U.S. BANK NATIONAL ASSOCIATION, as Trustee

--------------------------------------------------------------------------------

                      THIRTEENTH SUPPLEMENTAL INDENTURE TO
                        INDENTURE DATED DECEMBER 16, 1997
                            (SENIOR DEBT SECURITIES)

                           Dated as of March 24, 2006

--------------------------------------------------------------------------------

                           5.95% Senior Notes due 2036

================================================================================

<PAGE>

                                TABLE OF CONTENTS

                                                                            Page

                                    ARTICLE I

                       Relation to Indenture; Definitions

   Section 1.1.    RELATION TO INDENTURE.......................................1
   Section 1.2.    DEFINITIONS.................................................2

                                   ARTICLE II

                            The Series of Securities

   Section 2.1.    TITLE OF THE SECURITIES.....................................2
   Section 2.2.    LIMITATION ON AGGREGATE PRINCIPAL AMOUNT....................2
   Section 2.3.    PRINCIPAL PAYMENT DATE......................................2
   Section 2.4.    INTEREST AND INTEREST RATES.................................2
   Section 2.5.    PLACE OF PAYMENT............................................3
   Section 2.6.    REDEMPTION..................................................3
   Section 2.7.    DENOMINATION................................................5
   Section 2.8.    CURRENCY....................................................5
   Section 2.9.    FORM OF SECURITIES..........................................5
   Section 2.10.   SECURITIES REGISTRAR AND PAYING AGENT.......................5
   Section 2.11.   SINKING FUND OBLIGATIONS....................................5
   Section 2.12.   DEFEASANCE AND COVENANT DEFEASANCE..........................5
   Section 2.13.   IMMEDIATELY AVAILABLE FUNDS.................................5

                                   ARTICLE III

                                    Expenses

   Section 3.1.    PAYMENT OF EXPENSES.........................................5
   Section 3.2.    PAYMENT UPON RESIGNATION OR REMOVAL.........................5

                                   ARTICLE IV

                            Miscellaneous Provisions

   Section 4.1.    TRUSTEE NOT RESPONSIBLE FOR RECITALS........................6
   Section 4.2.    ADOPTION, RATIFICATION AND CONFIRMATION.....................6
   Section 4.3.    COUNTERPARTS................................................6
   Section 4.4.    GOVERNING LAW...............................................6

<PAGE>

                            THE ALLSTATE CORPORATION

                      THIRTEENTH SUPPLEMENTAL INDENTURE TO
                        INDENTURE DATED DECEMBER 16, 1997
                            (SENIOR DEBT SECURITIES)

                                  $650,000,000

                           5.95% Senior Notes due 2036

          THIRTEENTH SUPPLEMENTAL INDENTURE, dated as of March 24, 2006, between
THE ALLSTATE CORPORATION, a Delaware corporation (the "Company"), and U.S. BANK
NATIONAL ASSOCIATION, a national banking association, organized under the laws
of the United States, as successor in interest to STATE STREET BANK AND TRUST
COMPANY, a trust company organized under the laws of the Commonwealth of
Massachusetts, as Trustee (the "Trustee").

                                    RECITALS

          The Company has heretofore executed and delivered to the Trustee an
Indenture for Senior Debt Securities, dated as of December 16, 1997, as amended
by the Third Supplemental Indenture dated as of July 23, 1999 and the Sixth
Supplemental Indenture dated as of June 12, 2000 (the "Indenture"), providing
for the issuance from time to time of series of the Company's Securities.

          Section 301 of the Indenture provides for various matters with respect
to any series of Securities issued under the Indenture to be established in an
indenture supplemental to the Indenture.

          Section 901(7) of the Indenture provides for the Company and the
Trustee to enter into an indenture supplemental to the Indenture to establish
the form or terms of Securities of any series as provided by Sections 201 and
301 of the Indenture.

          NOW, THEREFORE, THIS THIRTEENTH SUPPLEMENTAL INDENTURE WITNESSETH:

          For and in consideration of the premises and the issuance of the
series of Securities provided for herein, it is mutually agreed, for the equal
and proportionate benefit of all Holders of the Securities of such series, as
follows:

                                   ARTICLE I

                       RELATION TO INDENTURE; DEFINITIONS

          Section 1.1. RELATION TO INDENTURE. This Thirteenth Supplemental
Indenture constitutes an integral part of the Indenture.

                                        1

<PAGE>

          Section 1.2. DEFINITIONS. For all purposes of this Thirteenth
Supplemental Indenture:

          (a) Capitalized terms used herein without definition shall have the
meanings specified in the Indenture;

          (b) All references herein to Articles and Sections, unless otherwise
specified, refer to the corresponding Articles and Sections of this Thirteenth
Supplemental Indenture; and

          (c) The terms "herein," "hereof," "hereunder" and other words of
similar import refer to this Thirteenth Supplemental Indenture.

                                   ARTICLE II

                            THE SERIES OF SECURITIES

          Section 2.1. TITLE OF THE SECURITIES. There shall be a series of
Securities designated the "5.95% Senior Notes due 2036" (the "Securities").

          Section 2.2. LIMITATION ON AGGREGATE PRINCIPAL AMOUNT. The aggregate
principal amount of the Securities shall initially be limited to $650,000,000.
The Company may, without the consent of the holders of the Securities, issue
additional Securities having the same interest rate, maturity date and other
terms as described in the related prospectus supplement and prospectus. Any
additional Securities, together with the Securities offered by the related
prospectus supplement, will constitute a single series of Securities under the
Indenture. No additional Securities may be issued if an Event of Default under
the Indenture has occurred and is continuing with respect to the Securities.

          Section 2.3. PRINCIPAL PAYMENT DATE. The principal amount of the
Securities outstanding (together with any accrued and unpaid interest) shall be
payable in a single installment on April 1, 2036, which date shall be the Stated
Maturity of the Securities Outstanding.

          Section 2.4. INTEREST AND INTEREST RATES. The rate of interest on each
Security shall be 5.95% per annum, accruing from March 24, 2006, or from the
most recent interest payment date (each such date, an "Interest Payment Date")
to which interest has been paid or duly provided for, payable semiannually in
arrears on April 1 and October 1 of each year commencing October 1, 2006 until
the principal thereof shall have become due and payable, and until the principal
thereof is paid or duly provided for or made available for payment. The amount
of interest payable on any Interest Payment Date shall be computed on the basis
of a 360-day year of twelve 30-day months. The amount of interest payable for
any partial period shall be computed on the basis of the actual number of days
elapsed in a 360-day year of twelve 30-day months. In the event that any date on
which interest is payable on any Security is not a Business Day, then payment of
interest payable on such date will be made on the next succeeding day that is a
Business Day (and without any interest or other payment in respect of any such
delay). A "Business Day" shall mean any day, other than a Saturday or Sunday, on
which banks in the City of New York and Boston, Massachusetts are not required
by law to

                                        2

<PAGE>

close. The interest installment so payable in respect of any Security, and
punctually paid or duly provided for, on any Interest Payment Date will, as
provided in the Indenture, be paid to the person in whose name such Security (or
one or more Predecessor Securities) is registered at the close of business on
March 15 or September 15 prior to such Interest Payment Date. Any such interest
installment not punctually paid or duly provided for in respect of any Security
shall forthwith cease to be payable to the registered Holder on such Regular
Record Date and may either be paid to the Person in whose name such Security (or
one or more Predecessor Securities) is registered at the close of business on a
Special Record Date to be fixed by the Trustee for the payment of such Defaulted
Interest, notice whereof shall be given to the Holders of this series of
Securities not less than 10 days prior to such Special Record Date, or be paid
at any time in any other lawful manner not inconsistent with the requirements of
any securities exchange on which the Securities of this series may be listed,
and upon such notice as may be required by such exchange, all as more fully
provided in the Indenture.

          Section 2.5. PLACE OF PAYMENT. The Place of Payment where the
Securities may be presented or surrendered for payment, where the Securities may
be surrendered for registration of transfer or exchange and where notices and
demand to or upon the Company in respect of the Securities and the Indenture may
be served shall be the Corporate Trust Office of the Trustee.

          Section 2.6. REDEMPTION.

          (a) The Company may redeem the Securities, in whole or in part, at any
time at a redemption price equal to the greater of (i) 100% of the principal
amount of such securities to be redeemed or (ii) an amount, as determined by an
Independent Investment Banker, equal to the sum of the present values of the
remaining scheduled payments of principal of and interest on the securities to
be redeemed (not including any portion of such payments of interest accrued to
the date of redemption) discounted to the redemption date on a semiannual basis
(assuming a 360-day year consisting of twelve 30-day months) at the Adjusted
Treasury Rate, plus 20 basis points, plus, in either of the above cases, accrued
and unpaid interest thereon to the redemption date.

          (b) For the purposes of this Section 2.6,

          "Adjusted Treasury Rate" means, with respect to any redemption date:

          -    the yield, under the heading which represents the average for the
               immediately preceding week, appearing in the most recently
               published statistical release designated "H.15(519)" published by
               the Board of Governors of the Federal Reserve System (or any
               successor publication which is published weekly by the Board of
               Governors of the Federal Reserve System and which establishes
               yields on actively traded United States Treasury securities
               adjusted to constant maturity) under the caption "Treasury
               Constant Maturities," for the maturity corresponding to the
               Comparable Treasury Issue. If no maturity is within three months
               before or after the Remaining Life, yields for the two published
               maturities most

                                        3

<PAGE>

               closely corresponding to the Comparable Treasury Issue shall be
               determined and the Adjusted Treasury Rate shall be interpolated
               or extrapolated from such yields on a straight line basis,
               rounding to the nearest month; or

          -    if such release (or any successor release) is not published
               during the week preceding the calculation date or does not
               contain such yields, the rate per annum equal to the semiannual
               equivalent yield to maturity of the Comparable Treasury Issue,
               calculated using a price for the Comparable Treasury Issue
               (expressed as a percentage of its principal amount) equal to the
               Comparable Treasury Price for such redemption date.

          The Adjusted Treasury Rate shall be calculated on the third business
day preceding the redemption date.

          "Comparable Treasury Issue" means the United States Treasury security
selected by an Independent Investment Banker as having a maturity comparable to
the remaining term of the securities to be redeemed that would be used, at the
time of selection and in accordance with customary financial practice, in
pricing new issues of corporate debt securities of comparable maturity to the
remaining term of such securities ("Remaining Life").

          "Comparable Treasury Price" means (i) the average of five Reference
Treasury Dealer Quotations for such redemption date, after excluding the highest
and lowest Reference Treasury Dealer Quotations, or (ii) if the Independent
Investment Banker obtains fewer than five such Reference Treasury Dealer
Quotations, the average of all such quotations.

          "Independent Investment Banker" means one of the Reference Treasury
Dealers appointed by us.

          "Reference Treasury Dealer" means:

          -    each of J.P. Morgan Securities Inc. and Morgan Stanley & Co.
               Incorporated, and their respective successors; provided, however,
               that if any of the foregoing shall cease to be a primary U.S.
               Government securities dealer in the United States (a "Primary
               Treasury Dealer"), the Company shall substitute therefor another
               Primary Treasury Dealer; and

          -    any three other Primary Treasury Dealers selected by the Company.

          "Reference Treasury Dealer Quotations" means, with respect to each
Reference Treasury Dealer and any redemption date, the average, as determined by
the Independent Investment Banker, of the bid and asked prices for the
Comparable Treasury Issue (expressed in each case as a percentage of its
principal amount) quoted in writing to the Independent Investment Banker at 5:00
p.m., New York City Time, on the third business day preceding such redemption
date.

                                        4

<PAGE>

          The Company will mail a notice of redemption at least 30 days but not
more than 60 days before the redemption date to each holder of the securities to
be redeemed. If less than all of the securities are to be redeemed, the trustee
will select, by such method as it will deem fair and appropriate, including pro
rata or by lot, the securities to be redeemed in whole or in part.

          Unless the Company defaults in payment of the redemption price, on and
after the redemption date, interest will cease to accrue on the securities or
portions thereof called for redemption.

          Section 2.7. DENOMINATION. The Securities of this series shall be
issuable only in registered form without coupons and in denominations of $2,000
and integral multiples of $1,000.

          Section 2.8. CURRENCY. Principal and interest on the Securities shall
be payable in such coin or currency of the United States of America that at the
time of payment is legal tender for payment of public and private debts.

          Section 2.9. FORM OF SECURITIES. The Securities shall be substantially
in the form attached as EXHIBIT A hereto.

          Section 2.10. SECURITIES REGISTRAR AND PAYING AGENT. The Trustee shall
serve initially as Securities Registrar and Paying Agent.

          Section 2.11. SINKING FUND OBLIGATIONS. The Company has no obligation
to redeem or purchase any Securities pursuant to any sinking fund or analogous
requirement or upon the happening of a specified event or at the option of a
Holder thereof.

          Section 2.12. DEFEASANCE AND COVENANT DEFEASANCE. The Company has
elected to have both Section 1302 (relating to defeasance) and Section 1303
(relating to covenant defeasance) applied to the Securities.

          Section 2.13. IMMEDIATELY AVAILABLE FUNDS. All payments of principal
and interest shall be made in immediately available funds.

                                  ARTICLE III

                                    EXPENSES

          Section 3.1. PAYMENT OF EXPENSES. In connection with the offering,
sale and issuance of the Securities, the Company, in its capacity as borrower
with respect to the Securities, shall pay all costs and expenses relating to the
offering, sale and issuance of the Securities, including commissions to the
underwriters payable pursuant to the Underwriting Agreement, dated March 21,
2006, and compensation and expenses of the Trustee under the Indenture in
accordance with the provisions of Section 607 of the Indenture.

          Section 3.2. PAYMENT UPON RESIGNATION OR REMOVAL. Upon termination of
this Thirteenth Supplemental Indenture or the Indenture or the removal or

                                        5

<PAGE>

resignation of the Trustee, unless otherwise stated, the Company shall pay to
the Trustee all amounts accrued to the date of such termination, removal or
resignation.

                                   ARTICLE IV

                            MISCELLANEOUS PROVISIONS

          Section 4.1. TRUSTEE NOT RESPONSIBLE FOR RECITALS. The recitals herein
contained are made by the Company and not by the Trustee, and the Trustee
assumes no responsibility for the correctness thereof. The Trustee makes no
representation as to the validity or sufficiency of this Thirteenth Supplemental
Indenture.

          Section 4.2. ADOPTION, RATIFICATION AND CONFIRMATION. The Indenture,
as supplemented and amended by this Thirteenth Supplemental Indenture, is in all
respects hereby adopted, ratified and confirmed.

          Section 4.3. COUNTERPARTS. This Thirteenth Supplemental Indenture may
be executed in any number of counterparts, each of which shall be an original,
but such counterparts shall together constitute but one and the same instrument.

          Section 4.4. GOVERNING LAW. THIS THIRTEENTH SUPPLEMENTAL INDENTURE AND
EACH SECURITY SHALL BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF THE STATE
OF NEW YORK AND SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES THEREOF.

                                        6

<PAGE>

          IN WITNESS WHEREOF, the parties hereto have caused this Thirteenth
Supplemental Indenture to be duly executed, and their respective corporate seals
to be hereunto affixed and attested, on the date or dates indicated in the
acknowledgments and as of the day and year first above written.

                                            THE ALLSTATE CORPORATION

                                            By:___________________________
                                                Name:
                                                Title:
ATTEST:

By:___________________________
    Name:
    Title:
                                            U.S. BANK NATIONAL
                                            ASSOCIATION, as
                                            Trustee

                                            By:___________________________
                                                Name:
                                                Title:

                                        7

<PAGE>

                                                                       EXHIBIT A

                           (FORM OF FACE OF SECURITY)

          This Security is a Global Security within the meaning of the Indenture
hereinafter referred to and is registered in the name of a Depositary or a
nominee of a Depositary. This Security is exchangeable for Securities registered
in the name of a person other than the Depositary or its nominee only in the
limited circumstances described in the Indenture, and no transfer of this
Security (other than a transfer of this Security as a whole by the Depositary to
a nominee of the Depositary or by a nominee of the Depositary to the Depositary
or another nominee of the Depositary) may be registered except in limited
circumstances.

          Unless this Security is presented by an authorized representative of
The Depository Trust Company (55 Water Street, New York, New York) to the issuer
or its agent for registration of transfer, exchange or payment, and any Security
issued is registered in the name of Cede & Co. or such other name as requested
by an authorized representative of The Depository Trust Company and any payment
hereon is made to Cede & Co., ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE
OR OTHERWISE BY A PERSON IS WRONGFUL since the registered owner hereof, Cede &
Co., has an interest herein.

Certificate No. ___                                          $__________________
                                                           CUSIP No. 020002 AT 8

                            THE ALLSTATE CORPORATION

                           5.95% Senior Notes due 2036

          THE ALLSTATE CORPORATION, a Delaware corporation (the "Company," which
term includes any successor corporation under the Indenture hereinafter referred
to), for value received, hereby promises to pay to CEDE & CO. or registered
assigns, the principal sum of
on April 1, 2036. The Company further promises to pay interest on said principal
sum outstanding from March 24, 2006, or from the most recent interest payment
date (each such date, an "Interest Payment Date") to which interest has been
paid or duly provided for, semiannually in arrears on April 1 and October 1 of
each year commencing October 1, 2006 at the rate of 5.95% per annum, until the
principal hereof shall have become due and payable and, until the principal
hereof is paid or duly provided for or made available for payment. The amount of
interest payable on any Interest Payment Date shall be computed on the basis of
a 360-day year of twelve 30-day months. The amount of interest payable for any
partial period shall be computed on the basis of the number of actual days
elapsed in a 360-day year of twelve 30-day months. In the event that any date on
which interest is payable on this Security is not a Business Day, then payment
of interest payable on such date will be made on the next succeeding day that is
a Business Day (and without any interest or other payment in respect of any such
delay). A "Business Day" shall mean any day, other than a Saturday or Sunday, on
which the banks in the City of New York and Boston, Massachusetts are

                                       A-1

<PAGE>

not required by law to close. The interest installment so payable, and
punctually paid or duly provided for, on any Interest Payment Date will, as
provided in the Indenture, be paid to the Person in whose name this Security (or
one or more Predecessor Securities) is registered at the close of business on
March 15 or September 15 prior to such Interest Payment Date. Any such interest
installment not punctually paid or duly provided for shall forthwith cease to be
payable to the registered Holder on such Regular Record Date and may either be
paid to the Person in whose name this Security (or one or more Predecessor
Securities) is registered at the close of business on a Special Record Date to
be fixed by the Trustee for the payment of such Defaulted Interest, notice
whereof shall be given to the Holder of this Security not less than 10 days
prior to such Special Record Date, or be paid at any time in any other lawful
manner not inconsistent with the requirements of any securities exchange on
which this Security may be listed, and upon such notice as may be required by
such exchange, all as more fully provided in the Indenture.

          The principal of (and premium, if any) and the interest on this
Security shall be payable at the office or agency of the Company maintained for
that purpose in the United States in such coin or currency of the United States
of America that at the time of payment is legal tender for payment of public and
private debts; PROVIDED, HOWEVER, that payment of interest may be made at the
option of the Company by check mailed to the registered Holder at such address
as shall appear in the Security Register. Notwithstanding the foregoing, so long
as the Holder of this Security is Cede & Co., the payment of the principal of
(and premium, if any) and interest on this Security will be made at such place
and to such account as may be designated by Cede & Co. All payments of principal
and interest hereunder shall be made in immediately available funds.

          Reference is hereby made to the further provisions of this Security
set forth on the reverse hereof, which further provisions shall for all purposes
have the same effect as if set forth at this place.

          Unless the certificate of authentication hereon has been executed by
the Trustee referred to on the reverse hereof by manual signature, this Security
shall not be entitled to any benefit under the Indenture or be valid for any
purpose.

                                       A-2

<PAGE>

          IN WITNESS WHEREOF, the Company has caused this instrument to be
executed.

                                            THE ALLSTATE CORPORATION

                                            By:_______________________________
                                               Name:
                                               Title:

Attest:

By:__________________________
    Name:
    Title:

                          CERTIFICATE OF AUTHENTICATION

          This is one of the Securities of the series designated herein referred
to in the within-mentioned Indenture.

Dated: March 24, 2006

U.S. BANK NATIONAL ASSOCIATION, as Trustee

By:_____________________________
    Authorized Signatory

                                       A-3

<PAGE>

                          (FORM OF REVERSE OF SECURITY)

          This Security is one of a duly authorized issue of securities of the
Company, designated as its 5.95% Senior Notes due 2036 (herein referred to as
the "Securities"), issued under and pursuant to an Indenture, dated as of
December 16, 1997 between the Company and State Street Bank and Trust Company,
as Trustee (herein called the "Trustee," which term includes any successor
trustee under the Indenture), as amended by the Third Supplemental Indenture
dated as of July 23, 1999 and the Sixth Supplemental Indenture dated as of June
12, 2000 and as supplemented by the Thirteenth Supplemental Indenture, dated as
of March 24, 2006, between the Company and the Trustee (the Indenture as so
amended and supplemented, the "Indenture"), to which Indenture and all
indentures supplemental thereto reference is hereby made for a description of
the rights, limitations of rights, obligations, duties and immunities thereunder
of the Trustee, the Company and the Holders of the Securities, and of the terms
upon which the Securities are, and are to be, authenticated and delivered.

          All terms used in this Security that are defined in the Indenture
shall have the meanings assigned to them in the Indenture.

          The Company may redeem the Securities, in whole or in part, at any
time at a redemption price equal to the greater of (i) 100% of the principal
amount of such securities to be redeemed or (ii) an amount, as determined by an
Independent Investment Banker, equal to the sum of the present values of the
remaining scheduled payments of principal of and interest on the securities to
be redeemed (not including any portion of such payments of interest accrued to
the date of redemption) discounted to the redemption date on a semiannual basis
(assuming a 360-day year consisting of twelve 30-day months) at the Adjusted
Treasury Rate, plus 20 basis points, plus, in either of the above cases, accrued
and unpaid interest thereon to the redemption date.

          "Adjusted Treasury Rate" means, with respect to any redemption date:

          -    the yield, under the heading which represents the average for the
               immediately preceding week, appearing in the most recently
               published statistical release designated "H.15(519)" published by
               the Board of Governors of the Federal Reserve System (or any
               successor publication which is published weekly by the Board of
               Governors of the Federal Reserve System and which establishes
               yields on actively traded United States Treasury securities
               adjusted to constant maturity) under the caption "Treasury
               Constant Maturities," for the maturity corresponding to the
               Comparable Treasury Issue. If no maturity is within three months
               before or after the Remaining Life, yields for the two published
               maturities most closely corresponding to the Comparable Treasury
               Issue shall be determined and the Adjusted Treasury Rate shall be
               interpolated or extrapolated from such yields on a straight line
               basis, rounding to the nearest month; or

                                       A-4

<PAGE>

          -    if such release (or any successor release) is not published
               during the week preceding the calculation date or does not
               contain such yields, the rate per annum equal to the semiannual
               equivalent yield to maturity of the Comparable Treasury Issue,
               calculated using a price for the Comparable Treasury Issue
               (expressed as a percentage of its principal amount) equal to the
               Comparable Treasury Price for such redemption date.

          The Adjusted Treasury Rate shall be calculated on the third business
day preceding the redemption date.

          "Comparable Treasury Issue" means the United States Treasury security
selected by an Independent Investment Banker as having a maturity comparable to
the remaining term of the securities to be redeemed that would be used, at the
time of selection and in accordance with customary financial practice, in
pricing new issues of corporate debt securities of comparable maturity to the
remaining term of such securities ("Remaining Life").

          "Comparable Treasury Price" means (i) the average of five Reference
Treasury Dealer Quotations for such redemption date, after excluding the highest
and lowest Reference Treasury Dealer Quotations, or (ii) if the Independent
Investment Banker obtains fewer than five such Reference Treasury Dealer
Quotations, the average of all such quotations.

          "Independent Investment Banker" means one of the Reference Treasury
Dealers appointed by us.

          "Reference Treasury Dealer" means:

          -    each of J.P. Morgan Securities Inc. and Morgan Stanley & Co.
               Incorporated, and their respective successors; provided, however,
               that if any of the foregoing shall cease to be a primary U.S.
               Government securities dealer in the United States (a "Primary
               Treasury Dealer"), the Company shall substitute therefor another
               Primary Treasury Dealer; and

          -    any three other Primary Treasury Dealers selected by the Company.

          "Reference Treasury Dealer Quotations" means, with respect to each
Reference Treasury Dealer and any redemption date, the average, as determined by
the Independent Investment Banker, of the bid and asked prices for the
Comparable Treasury Issue (expressed in each case as a percentage of its
principal amount) quoted in writing to the Independent Investment Banker at 5:00
p.m., New York City Time, on the third business day preceding such redemption
date.

          The Company will mail a notice of redemption at least 30 days but not
more than 60 days before the redemption date to each holder of the securities to
be redeemed. If less than all of the securities are to be redeemed, the trustee
will select, by such method as it will deem fair and appropriate, including pro
rata or by lot, the securities to be redeemed in whole or in part.

                                       A-5

<PAGE>

          Unless we default in payment of the redemption price, on and after the
redemption date, interest will cease to accrue on the securities or portions
thereof called for redemption.

          If an Event of Default with respect to Securities of this series shall
occur and be continuing, the principal of the Securities of this series may be
declared due and payable in the manner, with the effect and subject to the
conditions provided in the Indenture.

          The Indenture contains provisions for satisfaction, discharge and
defeasance at any time of the entire indebtedness of this Security upon
compliance by the Company with certain conditions set forth in the Indenture.

          The Indenture permits, with certain exceptions as therein provided,
the amendment thereof and the modification of the rights and obligations of the
Company and the rights of the Holders of the Securities of each series to be
affected under the Indenture at any time by the Company and the Trustee with the
consent of the Holders of a majority in principal amount of the Securities of
each series at the time Outstanding of each series to be affected. The Indenture
also contains provisions permitting Holders of specified percentages in
principal amount of the Securities of each series at the time Outstanding, on
behalf of the Holders of all Securities of such series, to waive compliance by
the Company with certain provisions of the Indenture and certain past defaults
under the Indenture and their consequences. Any such consent or waiver by the
Holder of this Security shall be conclusive and binding upon such Holder and
upon all future Holders of this Security and of any Security issued upon the
registration of transfer hereof or in exchange therefor or in lieu hereof,
whether or not notation of such consent or waiver is made upon this Security. No
reference herein to the Indenture and no provision of this Security or of the
Indenture (other than Section 1302 and Section 1303 of the Indenture) shall
alter or impair the obligation of the Company to pay the principal and interest
on the Security at the times, place and rate, and in the coin or currency,
herein prescribed.

          As provided in the Indenture and subject to certain limitations
therein set forth, the transfer of this Security is registrable in the
Securities Register, upon surrender of this Security for registration of
transfer at the office or agency of the Company maintained under Section 1002 of
the Indenture duly endorsed by, or accompanied by a written instrument of
transfer, in form satisfactory to the Company and the Securities Registrar, duly
executed by the Holder hereof or his or her attorney duly authorized in writing,
and thereupon one or more new Securities of this series, of authorized
denominations and for the same aggregate principal amount, will be issued to the
designated transferee or transferees. No service charge shall be made for any
such registration of transfer or exchange, but the Company may require payment
of a sum sufficient to cover any tax or other governmental charge payable in
connection therewith.

          Prior to due presentment of this Security for registration of
transfer, the Company, the Trustee and any agent of the Company or the Trustee
may treat the Person in whose name this Security is registered as the owner
hereof for all purposes, whether or not this Security be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.

                                       A-6

<PAGE>

          This Global Security is exchangeable for Securities in definitive form
only under certain limited circumstances set forth in the Indenture. Securities
of this series so issued are issuable only in registered form without coupons in
denominations of $2,000 and any integral multiples of $1,000. As provided in the
Indenture and subject to certain limitations herein and therein set forth,
Securities of this series so issued are exchangeable for a like aggregate
principal amount of Securities of this series of a different authorized
denomination, as requested by the Holder surrendering the same.

          The Company and, by its acceptance of this Security or a beneficial
interest therein, the Holder of, and any Person that acquires a beneficial
interest in, this Security agree that for United States federal, state and local
tax purposes it is intended that this Security constitute indebtedness.

          THE INTERNAL LAWS OF THE STATE OF NEW YORK SHALL GOVERN THE INDENTURE
AND THE SECURITIES WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

                                       A-7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]